[{"orgOrder":0,"company":"Pelthos Therapeutics","sponsor":"CHRO Merger","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Merger","leadProduct":"Berdazimer Sodium","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pelthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Pelthos Therapeutics \/ CHRO Merger","highestDevelopmentStatusID":"15","companyTruncated":"Pelthos Therapeutics \/ CHRO Merger"},{"orgOrder":0,"company":"Pelthos Therapeutics","sponsor":"Channel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Merger","leadProduct":"Berdazimer Sodium","moa":"NO","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pelthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Pelthos Therapeutics \/ Pelthos Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Pelthos Therapeutics \/ Pelthos Therapeutics"},{"orgOrder":0,"company":"Pelthos Therapeutics","sponsor":"Murchinson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"Berdazimer Sodium","moa":"NO","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pelthos Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Topical Gel","sponsorNew":"Pelthos Therapeutics \/ Murchinson","highestDevelopmentStatusID":"15","companyTruncated":"Pelthos Therapeutics \/ Murchinson"},{"orgOrder":0,"company":"Pelthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pelthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Pelthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pelthos Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Pelthos Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ACS Fall 2025
                          Not Confirmed
                          ACS Fall 2025
                          Not Confirmed

                          Details : Zelsuvmi (berdazimer sodium) is a nitric oxide releasing agent indicated for the topical treatment of molluscum contagiosum in adults and pediatric patients 1 year of age and older.

                          Product Name : Zelsuvmi

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 10, 2025

                          Lead Product(s) : Berdazimer Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ACS Fall 2025
                          Not Confirmed
                          ACS Fall 2025
                          Not Confirmed

                          Details : The combined company plans to launch Zelsuvmi (berdazimer) topical gel, a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum.

                          Product Name : Zelsuvmi

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 02, 2025

                          Lead Product(s) : Berdazimer Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Channel Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          03

                          ACS Fall 2025
                          Not Confirmed
                          ACS Fall 2025
                          Not Confirmed

                          Details : Pelthos will initially focus on the launch and commercialization of Zelsuvmi (berdazimer) topical gel, a nitric oxide releasing agent indicated for the topical treatment of molluscum contagiosum.

                          Product Name : Zelsuvmi

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 02, 2025

                          Lead Product(s) : Berdazimer Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Murchinson

                          Deal Size : $50.1 million

                          Deal Type : Private Placement

                          blank

                          04

                          ACS Fall 2025
                          Not Confirmed
                          ACS Fall 2025
                          Not Confirmed

                          Details : The combined company will initially focus on accelerating the commercialization of Pelthos’ Zelsuvmi (berdazimer sodium) topical gel for the treatment of Molluscum contagiosum infections.

                          Product Name : Zelsuvmi

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 17, 2025

                          Lead Product(s) : Berdazimer Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : CHRO Merger

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank